158 related articles for article (PubMed ID: 37023015)
21. Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer.
He CZ; Zhang KH; Li Q; Liu XH; Hong Y; Lv NH
BMC Gastroenterol; 2013 May; 13():87. PubMed ID: 23672279
[TBL] [Abstract][Full Text] [Related]
22. Single and combined use of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and carcinoembryonic antigen in diagnosing gastric cancer.
Wu Y; Jiang M; Qin Y; Lin F; Lai M
Clin Chim Acta; 2018 Jun; 481():20-24. PubMed ID: 29476736
[TBL] [Abstract][Full Text] [Related]
23. Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer.
Iwanicki-Caron I; Di Fiore F; Roque I; Astruc E; Stetiu M; Duclos A; Tougeron D; Saillard S; Thureau S; Benichou J; Paillot B; Basuyau JP; Michel P
J Clin Oncol; 2008 Aug; 26(22):3681-6. PubMed ID: 18669452
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic Value of Serum Biomarkers for Intrahepatic Cholangiocarcinoma.
Li Y; Huang Y; Chen J
J Coll Physicians Surg Pak; 2019 Oct; 29(10):962-966. PubMed ID: 31564271
[TBL] [Abstract][Full Text] [Related]
25. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer.
Wang G; Qin Y; Zhang J; Zhao J; Liang Y; Zhang Z; Qin M; Sun Y
Int J Mol Sci; 2014 May; 15(6):9546-65. PubMed ID: 24879526
[TBL] [Abstract][Full Text] [Related]
26. CEA in breast ductal secretions as a promising biomarker for the diagnosis of breast cancer: a systematic review and meta-analysis.
Tang S; Zhou F; Sun Y; Wei L; Zhu S; Yang R; Huang Y; Yang J
Breast Cancer; 2016 Nov; 23(6):813-819. PubMed ID: 26898373
[TBL] [Abstract][Full Text] [Related]
27. Identifying the Best Marker Combination in CEA, CA125, CY211, NSE, and SCC for Lung Cancer Screening by Combining ROC Curve and Logistic Regression Analyses: Is It Feasible?
Yang Q; Zhang P; Wu R; Lu K; Zhou H
Dis Markers; 2018; 2018():2082840. PubMed ID: 30364165
[TBL] [Abstract][Full Text] [Related]
28. [The value of serum human tumor protein P53 in colorectal cancer combined diagnosis and postoperative monitoring].
Fan P; Zhang Y; Deng F; Chen SH; Li M; Zhang Q
Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2670-2673. PubMed ID: 28910954
[No Abstract] [Full Text] [Related]
29. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
30. Serum microRNA-155 as a potential biomarker to track disease in breast cancer.
Sun Y; Wang M; Lin G; Sun S; Li X; Qi J; Li J
PLoS One; 2012; 7(10):e47003. PubMed ID: 23071695
[TBL] [Abstract][Full Text] [Related]
31. The utility of serum tumor markers CEA and CA 15-3 for breast cancer prognosis and their association with clinicopathological parameters.
Uygur MM; Gümüş M
Cancer Treat Res Commun; 2021; 28():100402. PubMed ID: 34082362
[TBL] [Abstract][Full Text] [Related]
32. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
[TBL] [Abstract][Full Text] [Related]
33. [Long non-coding RNA HOTAIR in plasma as a potential biomarker for breast cancer diagnosis].
Zhang KJ; Zhang Y; Luo ZL; Liu L; Yang J; Wu LC; Yu SS; Liu JB
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Apr; 36(4):488-92. PubMed ID: 27113175
[TBL] [Abstract][Full Text] [Related]
34. Serum Human Epididymis Protein-4 (HE4) - A novel Approach to Differentiate Malignant Frombenign Breast Tumors.
Sai Baba KSS; Rehman MA; Pradeep Kumar J; Fatima M; Raju GSN; Uppin SG; Mohammed N
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2509-2507. PubMed ID: 34452565
[TBL] [Abstract][Full Text] [Related]
35. [Value of the concentration and integrity of serum cell-free DNA for the clinical diagnosis of esophageal carcinoma].
Qiu YW; Shen XJ; Jin CJ; Cao XJ; Ju SQ
Zhonghua Zhong Liu Za Zhi; 2018 Dec; 40(12):905-910. PubMed ID: 30605980
[No Abstract] [Full Text] [Related]
36. Clinical value of CEA for detection of distant metastases in newly diagnosed breast cancer: comparison with CA 15-3.
Maccio G; Goussot V; Berriolo-Riedinger A; Riedinger JM
Ann Biol Clin (Paris); 2017 Aug; 75(4):431-441. PubMed ID: 28751288
[TBL] [Abstract][Full Text] [Related]
37. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients].
Ni J; Guo Z; Zhang L
Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649
[TBL] [Abstract][Full Text] [Related]
38. Methylated Septin 9 as a Promising Biomarker in the Diagnosis and Recurrence Monitoring of Colorectal Cancer.
Lu P; Zhu X; Song Y; Luo Y; Lin J; Zhang J; Cao Y; Huang Z
Dis Markers; 2022; 2022():7087885. PubMed ID: 35818587
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic value of soluble B7-H4 and carcinoembryonic antigen in distinguishing malignant from benign pleural effusion.
Jing X; Wei F; Li J; Dai L; Wang X; Jia L; Wang H; An L; Yang Y; Zhang G; Cheng Z
Clin Respir J; 2018 Mar; 12(3):986-990. PubMed ID: 28127951
[TBL] [Abstract][Full Text] [Related]
40. Tumor markers in serum and ascites in the diagnosis of benign and malignant ascites.
Zhu FL; Ling AS; Wei Q; Ma J; Lu G
Asian Pac J Cancer Prev; 2015; 16(2):719-22. PubMed ID: 25684514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]